ArticleCancer medicine2019

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy.

Chih-Hsun Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.